Scroll Top
dsm-firmenich reports H1 2023 results
f2m_dsm-firmenich _stock_exchange

DSM and Firmenich shared the first joint financial results since their merger, which was completed on May 8. Taste, Texture & Health is among the categories that performed well. The company estimates an FY 2023 on a pro forma basis Adjusted EBITDA of between EUR 1,800-1,900 million (versus EUR 2,275 million in FY 2022).

Geraldine Matchett and Dimitri de Vreeze, Co-CEOs, commented: “We are well advanced in the integration phase of the merger and excited by the positive response of customers to our enhanced business proposition, giving us even greater confidence in the delivery of our synergy targets. The performance of our Perfumery & Beauty and Taste, Texture & Health units in the first six months demonstrates the quality of these businesses and the synergy potential of the merger.

“Moving forward into the second semester of 2023, we will focus on optimizing our day-to-day operations, closely managing costs, driving growth, and fully executing our integration program to achieve our synergies. We have also accelerated some actions to restore the financial health of our vitamins business. With the amazing team we have at dsm-firmenich, I am very confident we can do all of this,” stated de Vreeze.

dsm-firmenich is organized into four distinct high-performing businesses, rooted in complementary world-class scientific research and manufacturing excellence: Perfumery & Beauty (P&B); Taste, Texture & Health (TTH); Health, Nutrition & Care (HNC); Animal Nutrition & Health (ANH).

Read more:

DSM and Firmenich to merge

Photo: dsm-firmenich